BRPI0410071A - métodos para usar no diagnóstico e prognóstico da artrite em um paciente, para usar no monitoramento do curso da artrite em um paciente, para avaliar a eficácia de um tratamento para artrite em um paciente, para triar um composto capaz de inibir a artrite em um paciente e para tratar artrite em um paciente, e, molécula de sirna - Google Patents

métodos para usar no diagnóstico e prognóstico da artrite em um paciente, para usar no monitoramento do curso da artrite em um paciente, para avaliar a eficácia de um tratamento para artrite em um paciente, para triar um composto capaz de inibir a artrite em um paciente e para tratar artrite em um paciente, e, molécula de sirna

Info

Publication number
BRPI0410071A
BRPI0410071A BRPI0410071-9A BRPI0410071A BRPI0410071A BR PI0410071 A BRPI0410071 A BR PI0410071A BR PI0410071 A BRPI0410071 A BR PI0410071A BR PI0410071 A BRPI0410071 A BR PI0410071A
Authority
BR
Brazil
Prior art keywords
patient
arthritis
methods
monitoring
course
Prior art date
Application number
BRPI0410071-9A
Other languages
English (en)
Inventor
Edward R Lavallie
Lisa A Collins-Racie
Maya Arai
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0410071A publication Critical patent/BRPI0410071A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rehabilitation Therapy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"MéTODOS PARA USAR NO DIAGNóSTICO E PROGNóSTICO DA ARTRITE EM UM PACIENTE, PARA USAR NO MONITORAMENTO DO CURSO DA ARTRITE EM UM PACIENTE, PARA AVALIAR A EFICáCIA DE UM TRATAMENTO PARA ARTRITE EM UM PACIENTE, PARA TRIAR UM COMPOSTO CAPAZ DE INIBIR A ARTRITE EM UM PACIENTE E PARA TRATAR ARTRITE EM UM PACIENTE, E, MOLéCULA DE SIRNA". A presente invenção está fundamentada na verificação de que a expressão de <sym>PKC é aumentada nos tecidos de pacientes com artrite quando comparado com indivíduos normais. Conseqüentemente, a presente invenção fornece métodos de diagnosticar, prognosticar e monitorar o curso da artrite em um paciente com base na expressão de gene <sym>PKC aumentada em tecido artrítico. A presente invenção ainda fornece compostos que inibem a expressão de <sym>PKC para o uso como remédios no tratamento de artrite, incluindo, mas não limitado a, polinucleotídeos e polipeptídeos inibitórios, inibidores de moléculas pequenas e peptídeo. Além disso, a presente invenção fornece formulações farmacêuticas e vias de administração para tais remédios, assim como a métodos para avaliar a sua eficácia.
BRPI0410071-9A 2003-05-08 2004-05-10 métodos para usar no diagnóstico e prognóstico da artrite em um paciente, para usar no monitoramento do curso da artrite em um paciente, para avaliar a eficácia de um tratamento para artrite em um paciente, para triar um composto capaz de inibir a artrite em um paciente e para tratar artrite em um paciente, e, molécula de sirna BRPI0410071A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46898703P 2003-05-08 2003-05-08
US49127403P 2003-07-31 2003-07-31
PCT/US2004/014759 WO2004104217A2 (en) 2003-05-08 2004-05-10 Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases

Publications (1)

Publication Number Publication Date
BRPI0410071A true BRPI0410071A (pt) 2006-05-23

Family

ID=33479253

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410071-9A BRPI0410071A (pt) 2003-05-08 2004-05-10 métodos para usar no diagnóstico e prognóstico da artrite em um paciente, para usar no monitoramento do curso da artrite em um paciente, para avaliar a eficácia de um tratamento para artrite em um paciente, para triar um composto capaz de inibir a artrite em um paciente e para tratar artrite em um paciente, e, molécula de sirna

Country Status (9)

Country Link
US (2) US7638482B2 (pt)
EP (1) EP1629283A2 (pt)
JP (1) JP2007515940A (pt)
CN (1) CN1860371B (pt)
AU (1) AU2004242105B2 (pt)
BR (1) BRPI0410071A (pt)
CA (1) CA2525012A1 (pt)
MX (1) MXPA05011777A (pt)
WO (1) WO2004104217A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160062A1 (en) * 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20100196509A1 (en) 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
WO2011063161A2 (en) 2009-11-20 2011-05-26 The Regents Of The University Of California Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69323185T2 (de) * 1992-02-24 1999-07-08 Smithkline Beecham Corp., Philadelphia, Pa. 19101 Proteinkinase c-inhibitor
US6235723B1 (en) * 1992-03-16 2001-05-22 Isis Pharmaceuticals , Inc. Antisense oligonucleotide modulation of human protein kinase C-δ expression
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6368831B1 (en) * 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
KR20010108024A (ko) * 1998-12-17 2001-12-07 프리돌린 클라우스너, 롤란드 비. 보레르 단백질 키나제 억제제로서의 4,5-피라진옥신돌
JP2003503360A (ja) * 1999-06-24 2003-01-28 ファルマシア コーポレイション 炎症性疾患の処置のための併用療法
ES2213996T3 (es) * 1999-12-08 2004-09-01 Centre National De La Recherche Scientifique (Cnrs) Uso de himenialdisina o sus derivados en la fabricacion de medicamentos.
US6608105B2 (en) * 2000-12-18 2003-08-19 Meiji Dairies Corporation TNF-α production inhibitor comprising kavalactone as an active ingredient

Also Published As

Publication number Publication date
JP2007515940A (ja) 2007-06-21
AU2004242105B2 (en) 2009-05-28
US20040259136A1 (en) 2004-12-23
CA2525012A1 (en) 2004-12-02
WO2004104217A3 (en) 2005-11-24
WO2004104217A2 (en) 2004-12-02
CN1860371B (zh) 2010-11-24
EP1629283A2 (en) 2006-03-01
US7638482B2 (en) 2009-12-29
MXPA05011777A (es) 2006-01-26
CN1860371A (zh) 2006-11-08
AU2004242105A1 (en) 2004-12-02
US20100062448A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
Roujeau et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985
Eriksen et al. Pain, quality of life and recovery after laparoscopic ventral hernia repair
Marzetti et al. Serum levels of C-terminal agrin fragment (CAF) are associated with sarcopenia in older hip fractured patients
Jawhar et al. Tourniquet-induced ischaemia during total knee arthroplasty results in higher proteolytic activities within vastus medialis cells: a randomized clinical trial
Fallowfield Acceptance of adjuvant therapy and quality of life issues
BR0111473A (pt) Métodos para triar um indivìduo quanto a uma doença de armazenagem de glicogênio, para triar um indivìduo quanto à doença de pompe, para monitorar a condição clìnica de um indivìduo com doença de pompe, para estimar a eficácia de um regime terapêutico em um indivìduo com doença de pompe e para determinar a concentração de um oligossacarìdeo em uma amostra biológica
BRPI0410071A (pt) métodos para usar no diagnóstico e prognóstico da artrite em um paciente, para usar no monitoramento do curso da artrite em um paciente, para avaliar a eficácia de um tratamento para artrite em um paciente, para triar um composto capaz de inibir a artrite em um paciente e para tratar artrite em um paciente, e, molécula de sirna
Öner et al. Predicting postoperative pain with neutrophil/lymphocyte ratio after arthroscopic rotator cuff repair
Morrison et al. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD)
Miaskowski Women and pain
Hua et al. Clinical Study of Acupotomy for Knee Osteoarthritis Based on the Meridian‐Sinew Theory: A Randomized Controlled Clinical Trial
Stroethoff et al. Impact of Ca2+-sensitive potassium channels in levosimendan-induced postconditioning
Tsigelny et al. Development of a pharmacophore model for the catecholamine release-inhibitory peptide catestatin: virtual screening and functional testing identify novel small molecule therapeutics of hypertension
AU2014308704B2 (en) Multiple myeloma treatment
Staud et al. Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial
Vibholm et al. Activated N‐methyl‐D‐aspartate receptor ion channels detected in focal epilepsy with [18F] GE‐179 positron emission tomography
Virit et al. Lack of pain in schizophrenia: a patient whose arm was burned and amputated
BRPI0409409A (pt) métodos para tratar doenças proliferativas e para monitorar a eficácia de tratamento de doenças proliferativas
McDonald et al. Effect of acipimox on skeletal muscle biochemistry, structure and function in older people with probable sarcopenia: an experimental medicine study
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
Sáinz‐Gil et al. Kaposi sarcoma in patients on tumour necrosis factor alpha inhibitors: a case–noncase study.
Liu et al. Serum concentrations of fibrinogen in patients with spinal cord injury and its relationship with neurologic function
Turedi et al. First time, low dose citalopram use-related serotonin syndrome
Wagner Jr The future
Zielaskowski et al. Multiple neuromas coexisting with rheumatoid synovitis and a rheumatoid nodule

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.